Related Experiment Video
Updated: Nov 10, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Determining Which Hospitalized Coronavirus Disease 2019 Patients Require Urgent Echocardiography
Neal Yuan1, Stephanie Wu1, Florian Rader1
1Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Insights
Biomarkers like troponin and B-type natriuretic peptide (BNP) can help identify COVID-19 patients who may not need immediate echocardiography. Normal levels of these cardiac biomarkers suggest transthoracic echocardiography (TTE) can be safely delayed, reducing transmission risks.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Diagnostics
Background:
- Hospitalized coronavirus disease 2019 (COVID-19) patients frequently exhibit abnormal transthoracic echocardiography (TTE) findings.
- Performing TTE on COVID-19 patients increases disease transmission risks, yet it's unclear which patients can safely defer this procedure.
- The utility of common biomarkers, troponin and B-type natriuretic peptide (BNP), in guiding TTE decisions for COVID-19 patients remains under investigation.
Purpose of the Study:
- To determine if troponin and BNP levels can help identify COVID-19 patients for whom TTE can be safely delayed.
- To assess the association between cardiac biomarkers and urgent echocardiographic findings in COVID-19 patients.
- To evaluate the potential of a biomarker-based rule for triaging TTE in COVID-19 patients.
Main Methods:
- Retrospective study of COVID-19 patients hospitalized between March 2020 and January 2021.
- Analysis of electronic health records and chart reviews for patients who underwent TTE and had troponin and BNP measured.
- Logistic regression used to identify predictors of urgent echocardiographic findings.
Main Results:
- Urgent echocardiographic findings were present in 24.2% of 434 hospitalized COVID-19 patients.
- Elevated troponin (>0.04 ng/mL) and BNP (>100 pg/mL) were significant predictors of urgent TTE findings.
- 95.1% of all patients and 91.3% of ICU patients with normal troponin and BNP showed no urgent TTE findings.
Conclusions:
- Troponin and BNP levels are strongly associated with urgent echocardiographic findings in COVID-19 patients.
- These biomarkers may be incorporated into triage algorithms to safely defer TTE during the peak infection period.
- Utilizing biomarkers can help mitigate transmission risks associated with TTE in COVID-19 patients.
Background:
Patients hospitalized with coronavirus disease 2019 (COVID-19) often have abnormal findings on transthoracic echocardiography (TTE). However, although not all abnormalities on TTE result in changes in clinical management, performing TTE in recently infected patients increases disease transmission risks. It remains unknown whether common biomarker tests, such as troponin and B-type natriuretic peptide (BNP), can help distinguish in which patients with COVID-19 TTE may be safely delayed until infection risks subside.
Methods:
Using electronic health records data and chart review, the authors retrospectively studied all patients hospitalized with COVID-19 in a multisite health care system from March 1, 2020, to January 15, 2021, who underwent TTE within 14 days of their first positive COVID-19 result and had BNP and troponin measured before or within 7 days of TTE. The primary outcome was the presence of one or more urgent echocardiographic findings, defined as left ventricular ejection fraction ≤ 35%, wall motion score index ≥ 1.5, moderate or greater right ventricular dysfunction, moderate or greater pericardial effusion, intracardiac thrombus, pulmonary artery systolic pressure > 50 mm Hg, or at least moderate to severe valvular disease. Stepwise logistic regression was conducted to determine biomarkers and comorbidities associated with the outcome. The performance of a rule for classifying TTE using troponin and BNP was evaluated.
Results:
Four hundred thirty-four hospitalized and 151 intensive care unit patients with COVID-19 were included. Urgent findings on TTE were present in 105 patients (24.2%). Troponin and BNP were abnormal in 311 (71.7%). Heart failure (odds ratio, 5.41; 95% CI, 2.61-11.68), troponin > 0.04 ng/mL (odds ratio, 4.40; 95% CI, 2.05-10.05), and BNP > 100 pg/mL (odds ratio, 5.85; 95% CI, 2.35-16.09) remained significant predictors of urgent findings on TTE after stepwise selection. No urgent findings on TTE were seen in 95.1% of all patients and in 91.3% of intensive care unit patients with normal troponin and BNP.
Conclusions:
Troponin and BNP were highly associated with urgent echocardiographic findings and may be used in triaging algorithms for determining in which patients TTE can be safely delayed until after their peak infectious window has passed.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Imaging Studies for Cardiovascular System II:Types of Echocardiography
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
Cardiomyopathy II: Dilated Cardiomyopathy
Dysrhythmias V: Evaluating Dysrhythmias

